Human Papillomavirus Antibody Reference Reagents for Use in Postvaccination Surveillance Serology

Correlation between direct ELISA, single epitope-based inhibition ELISA and Pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine

(2011) Francis J. Dessy et al.   Human vaccines & immunotherapeutics

Neutralization of non-vaccine human papillomavirus pseudoviruses from the A7 and A9 species groups by bivalent HPV vaccine sera

(2011) Eve Draper et al.   VACCINE

HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection

(2011) Troy J. Kemp et al.   VACCINE

The first international standard for antibodies to HPV 16

(2011) Morag Ferguson et al.   VACCINE

Vaccines to Prevent Infections by Oncoviruses

(2010) John T. Schiller et al.   Annual Review of Microbiology

Measuring serum antibody to human papillomavirus following infection or vaccination

(2010) Ian H. Frazer   GYNECOLOGIC ONCOLOGY

Current understanding of the mechanism of HPV infection

(2010) John T. Schiller et al.   GYNECOLOGIC ONCOLOGY

Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication

(2010) Ni Li et al.   INTERNATIONAL JOURNAL OF CANCER

Validation of multiplexed human papillomavirus serology using pseudovirions bound to heparin-coated beads

(2010) H. Faust et al.   JOURNAL OF GENERAL VIROLOGY

A Pooled Analysis of Continued Prophylactic Efficacy of Quadrivalent Human Papillomavirus (Types 6/11/16/18) Vaccine against High-grade Cervical and External Genital Lesions

(2009) S. K. Kjaer et al.   Cancer Prevention Research

Immunogenicity Testing in Human Papillomavirus Virus‐Like‐Particle Vaccine Trials

(2009) John T. Schiller et al.   JOURNAL OF INFECTIOUS DISEASES

The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus‐Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV‐Naive Women Aged 16–26 Years

(2009) Darron R. Brown et al.   JOURNAL OF INFECTIOUS DISEASES

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

(2009) J Paavonen et al.   LANCET

Vaccines: Correlates of Vaccine‐Induced Immunity

(2008) Stanley A. Plotkin   CLINICAL INFECTIOUS DISEASES

Seroprevalence of 34 Human Papillomavirus Types in the German General Population

(2008) Kristina M. Michael et al.   PLoS Pathogens